Source:http://linkedlifedata.com/resource/pubmed/id/12297844
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4 Pt 1
|
pubmed:dateCreated |
2002-9-25
|
pubmed:abstractText |
To determine whether a higher dosage of interferon (IFN) and/or a prolonged time of administration may improve the efficacy of combination therapy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C relapsing after 1 or more previous treatment courses with IFN monotherapy. Group A (n = 70) received 3 MU IFN alfa-2b 3 times per week plus ribavirin 1,000 mg/d for 12 months; group B (n = 70) received 5 MU 3 times per week plus ribavirin for 12 months; group C (n = 82) received 3 MU 3 times per week plus ribavirin for 6 months, and group D (n = 73) received 5 MU 3 times per week plus ribavirin for 6 months. The primary end point was the clearance of viremia at the end of 6-month follow-up: test results for hepatitis C virus (HCV)-RNA were negative in 54% of group A, 56% of group B, 40% of group C, and 49% of group D patients (P = NS). Among patients with genotype 1 and 4, the sustained response was significantly higher in groups A and B than in group C (45%, 49% vs. 22%, P =.03; group D = 33%, P = NS). In patients with genotype 2 and 3, the sustained virologic response was not affected by the different regimens (group A = 69%, group B = 68%, group C = 62%, group D = 71%, P = NS). In conclusion, duration of therapy rather than IFN dosage is more important in increasing the sustained virologic rate among HCV-positive patients with genotype 1 and 4 relapsing after IFN monotherapy; patients with genotypes 2 and 3 can be effectively retreated with a 6-month course of combination therapy, avoiding unnecessary side effects and waste of resources.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0270-9139
|
pubmed:author |
pubmed-author:AndreoniMassimoM,
pubmed-author:BiglinoAlbertoA,
pubmed-author:CarenziSilviaS,
pubmed-author:CaritiGiuseppeG,
pubmed-author:CiancioAlessiaA,
pubmed-author:CicconeGiovanninoG,
pubmed-author:CroceGuidoG,
pubmed-author:MancaAldoA,
pubmed-author:OliveroAldaA,
pubmed-author:OrsiPier GiulioPG,
pubmed-author:RizzettoMarioM,
pubmed-author:RoffiLuigiL,
pubmed-author:SaraccoGiorgioG,
pubmed-author:SmedileAntoninaA,
pubmed-author:TaboneMarcoM,
pubmed-author:TapperoGianfrancoG
|
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
959-66
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12297844-Adult,
pubmed-meshheading:12297844-Antiviral Agents,
pubmed-meshheading:12297844-Biopsy,
pubmed-meshheading:12297844-Drug Therapy, Combination,
pubmed-meshheading:12297844-Female,
pubmed-meshheading:12297844-Follow-Up Studies,
pubmed-meshheading:12297844-Hepacivirus,
pubmed-meshheading:12297844-Hepatitis C, Chronic,
pubmed-meshheading:12297844-Humans,
pubmed-meshheading:12297844-Interferon-alpha,
pubmed-meshheading:12297844-Liver,
pubmed-meshheading:12297844-Male,
pubmed-meshheading:12297844-Middle Aged,
pubmed-meshheading:12297844-Multivariate Analysis,
pubmed-meshheading:12297844-RNA, Viral,
pubmed-meshheading:12297844-Recombinant Proteins,
pubmed-meshheading:12297844-Recurrence,
pubmed-meshheading:12297844-Ribavirin,
pubmed-meshheading:12297844-Treatment Outcome,
pubmed-meshheading:12297844-Viral Load
|
pubmed:year |
2002
|
pubmed:articleTitle |
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
|
pubmed:affiliation |
Dipartimento di Gastroenterologia, Ospedale Molinette, Torino, Italy. g.saracco@tin.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|